EHR care-complexity score tracks CLABSI risk in ICU adults

This study introduces an electronic health record (EHR)-derived care-exposure burden marker that identifies critically ill patients at elevated risk of central line-associated bloodstream infection, offering pharmacists a potential prioritization signal for line stewardship and antimicrobial oversight.

central line-associated bloodstream infectionCLABSIcentral venous catheterhealthcare-associated infectionelectronic health recordsMIMIC-IVeICUcritical careretrospective cohortinfection preventionantimicrobial stewardship Clinical Pharmacy Practice

Background Information

Higher care-exposure burden increases CLABSI risk in critical care.

Central line-associated bloodstream infections (CLABSIs) are significant concerns in intensive care units, impacting patient outcomes and healthcare costs. Patients with higher care-exposure burden scores had higher odds of developing adjudicated CLABSI or CLABSI-like bloodstream infection, with odds ratios up to 4.99 in the highest quartile. The score serves as a marker of cumulative care complexity for infection prevention but requires prospective validation before clinical use. Higher EHR-derived care-exposure burdens correlate with increased CLABSI risk, highlighting the need for infection-prevention strategies.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Li N, Huang J, Liu J, He Y

Citation: Li N, Huang J, Liu J, et al. Electronic health record-derived care-exposure burden and central line-associated bloodstream infection among critically ill adults: a multi-source retrospective cohort study. Frontiers in public health. 2026;14:1883942. doi:10.3389/fpubh.2026.1883942

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →